Nathan Denlinger, DO, MS

home / authors / nathan-denlinger-do-ms

Articles

Beyond Salvage: When to Move to CAR T in Relapsed DLBCL

Krish Patel, MD; Saurabh Dahiya, MD, FACP;Nathan Denlinger, DO, MS ;Mohamed M. Hegazi, MD;Samuel Yamshon, MD

March 3rd 2025

Panelists discuss, when evaluating chimeric antigen receptor T-cell (CAR T) therapy for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), how key considerations include the patient’s fitness, disease burden, prior treatment response, and timing of referral. The limitations of traditional salvage therapy, with historically poor outcomes, must be weighed against CAR T’s potential for durable remissions despite its risks and complexities.

DLBCL in Focus: Transforming Outcomes With CAR T Therapy

Krish Patel, MD; Saurabh Dahiya, MD, FACP;Nathan Denlinger, DO, MS ;Mohamed M. Hegazi, MD;Samuel Yamshon, MD

March 3rd 2025

Panelists discuss how the diffuse large B-cell lymphoma (DLBCL) treatment landscape has seen significant evolution with the integration of targeted therapies and chimeric antigen receptor T-cell treatments, supplementing traditional R-CHOP. However, early relapsed/refractory cases remain challenging due to complex tumor biology and resistance mechanisms. This underscores the need for better up-front risk stratification tools and biomarker-driven treatment selection.